Table 5 Patients’ baseline characters in parenchymal hematoma (PH) type1 and type2.
Demographic data | (Non-HT group), N = 464 | Parenchymal hematoma 1, N = 14 | P-value | Parenchymal hematoma 2, N = 11 | P-value |
|---|---|---|---|---|---|
Gender, no, (percentage) | |||||
Male, no, (percentage) | 288.0 (62.1%) | 9.0 (64.3%) | 0.87 | 8.0 (72.7%) | 0.47 |
Age at time of presentation, median (IQR) | 61.0 (58.0–66.0) | 59.0 (59.0–65.0) | 0.52 | 59.0 (58.0–70.0) | 0.40 |
Location of infarction, no, (percentage) | |||||
Anterior circulation, no, (percentage) | 320.0 (69%) | 11.0 (78.6%) | 0.44 | 9.0 (81.8%) | 0.36 |
NIHSS at time of admission, median (IQR) | 10 (7.3–17.0) | 18.0 (15.0–20.0) | < 0.001* | 17.0 (14.0–20.0) | < 0.001* |
Door to needle time (min.), median (IQR) | 60.0 (55.0–66.0) | 55.0 (50.0–67.0) | 0.50 | 59.0 (50.0–69.0) | 0.51 |
Time of receiving IV rtPA from stroke onset (min.), median (IQR) | 174.0 (163.0–200.0) | 175.0 (155.0-200.0) | 0.28 | 175.0 (155.0-200.0) | 0.63 |
Patients on antiplatelets before stroke | |||||
Aspirin and clopidogrel | 120.0 (25.9%) | 4.0 (28.6%) | 0.82 | 2.0 (18.2%) | 0.56 |
Aspirin | 114.0 (24.6%) | 4.0 (28.6%) | 0.69 | 3.0 (27.3%) | 0.84 |
Clopidogrel | 90.0 (19.4%) | 2.0 (14.3%) | 0.63 | 2.0 (18.2%) | 0.52 |
Ticagrelor | 15.0 (3.2%) | 1.0 (7.1%) | 0.44 | 1.0 (9.1%) | 0.30 |
Patients on anticoagulants before stroke | |||||
Warfarin | 18.0 (3.9%) | 1.0 (7.1%) | 0.54 | 1.0 (9.1%) | 0.38 |
Rivaroxaban | 14.0 (3.0%) | 1.0 (7.1%) | 0.38 | 1.0 (9.1%) | 0.26 |
Apixaban | 10.0 (2.2%) | 0 | 1.0 (9.1%) | 0.13 | |
